Skip to main content

Table 2 Overview of affinity/avidity data of candidate therapeutic antibodies

From: A walk through tau therapeutic strategies

ANTIBODY

EPITOPE

AFFINITY

AVIDITY

TARGET (IN SPR)

NOTE

REFERENCE

HJ8.5

aa25-30

nd.

0.4 pM

Human Tau2N4R

tau immobilized to a high level (> 3000 RU)

[375]

HJ9.4

aa7-13

nd.

7 nM

Human Tau2N4R

tau immobilized to a high level (> 3000 RU)

[375]

HJ9.3

aa306-320

nd.

100 pM

Human Tau2N4R

tau immobilized to a high level (> 3000 RU)

[375]

ACI-5400

aa393-408(pS396)

38 nM

nd.

Tau393-408(pS396/pS404)

tau immobilized to a low level (130 RU)

[321]

DC8E8

Tetratope in the repeat region of tau (aa268-367)

91 nM

nd.

Human Tau2N4R

Antibody immobilized to a low level (230-250 RU)

[168]

DC8E8

Tetratope in the repeat region of tau (aa268-367)

14 nM

nd.

Pathological Tau151-391_4R

Antibody immobilized to a low level (230-250 RU)

[168]

derived from MC1

aa7-9; aa312-322

235

nd.

monomeric tau

Antibody immobilized at unknown density

[135]

derived from MC1

aa7-9; aa312-322

nd.

< 0.22 nM

tau aggregate

Antibody immobilized at unknown density

[135]

  1. nd Not defined, SPR Surface plasmon resonance spectroscopy